Roche Reports Flat Diagnostics Revenues in H1
At constant exchange rates, diagnostics revenues were up 2 percent, primarily due to the immunodiagnostics business.
FDA Approves Roche's PD-L1 Test for Bladder Cancer
The Ventana PD-L1 assay was approved as a complementary diagnostic for bladder cancer patients being considered for treatment with the immunotherapy Imfinzi.
Loxo Oncology, Ventana Medical Systems Partner to Develop CDx
The companies are aiming to develop and commercialize a test to identify patients likely to respond to Loxo's cancer drug larotrectinib.
Roche's Ventana Lays Off 84 in Bid to Address Business Challenges
In October, Roche reported the tissue diagnostics business contributed 8 percent to diagnostics sales in the first nine months of 2016.
Transgenomic to Share Melbourne Research Data With Ventana Medical Systems
The agreement gives Ventana access to results from a collaboration and licensing agreement that Transgenomic made separately with the University of Melbourne.